RecruitingPhase 2NCT05968768
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Studying Skeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anna Raciborska
- Principal Investigator
- Anna Raciborska, Prof.the Institue of Mother and Child
- Intervention
- Naxitamab(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2023 – 2028
Study locations (2)
- Mother and Child Institute, Warsaw, Mazowian, Poland
- Wroclaw Medical University, Wroclaw, Poland
Collaborators
Wroclaw Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05968768 on ClinicalTrials.govOther trials for Skeletal Ewing sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188532Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR TrialMayo Clinic
- RECRUITINGPHASE2NCT06699472A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibFudan University
- RECRUITINGPHASE1, PHASE2NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT06156410Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasChildren's Hospital of Philadelphia